The Republic of Translational Medicine
Bibliographic Data
| ID | 21300070 |
|---|---|
| Authors | Johnathon Liddicoat (King's College London, corresponding author), James Parish (King’s Information and Intellectual Property Hub, King’s College London), Mateo Aboy (0000-0002-5168-4321, University of Cambridge) |
| Year | 2026 |
| Pages | 1-26 |
| Publication date | 2026-06-16 |
| Open Access | Yes |
| Type | ARTICLE |
| Venue | The Cambridge Law Journal (JOURNAL) |
| Journal identifiers | ISSN: 0008-1973 • E-ISSN: 1469-2139 |
| Publisher | Cambridge University Press (CUP) (PUBLISHER) |
| DOI | 10.1017/s0008197326101469 |
| OpenAlex | W7164887929 |
| Language | EN |
Established pharmaceutical innovation theory holds that companies and patents are essential for developing new treatments. Yet, it does not adequately explain numerous clinical trials conducted by hospitals and universities. This paper introduces a new, complementary theory that describes a parallel system of innovation, focused on new uses of already authorised drugs, particularly once generics are available. These trials are driven by incentives previously associated with “open science” and “user innovation” rather than by patents and cost 90 per cent less than commercial equivalents. This “hidden” research system could regularly provide society with affordable treatments
Alternative medicine · Clinical trial · Incentive · The Republic · Translational medicine · Translational research · Biomedical Ethics and Regulation · Pharmaceutical Economics and Policy · Pharmaceutical industry and healthcare
| Highly cited | No |
|---|